Boudes Pol F 4
4 · GALECTIN THERAPEUTICS INC · Filed Jan 30, 2023
Insider Transaction Report
Form 4
Boudes Pol F
Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2023-01-26+50,000→ 50,000 totalExercise: $1.11Exp: 2033-01-26→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
- [F2]The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024.